Relationship between Clinical Effects, Serum Drug Concentration, and Concurrent Drug Interactions in Depressed Patients Treated with Citalopram, Fluoxetine, Clomipramine, Paroxetine or Venlafaxine
[en] The relationship between clinical effects and plasma concentrations of citalopram, fluoxetine, clomipramine, paroxetine and venlafaxine was studied in 119 cases of major depression. Clinical effects were evaluated using the Clinical Global Impression (CGI) improvement scale. Antidepressants were quantified by a separative chromatographic methodology. Plasma concentrations in responder patients were compared with the plasma concentrations proposed in literature as effective values. We found that the usual therapeutic window is convenient for citalopram and clomipramine, but could be reduced for fluoxetine and increased for venlafaxine and paroxetine. Concurrent drug interactions were also evaluated and clomipramine or citalopram plasma levels were found to be influenced by the presence of associated drugs. A larger study is needed, taking into account not only plasma concentrations and clinical effects, but also some pharmacokinetic data, especially the metabolic activity characterising the patient, and the presence or not of associated drugs. Copyright 2000 John Wiley
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Charlier, Corinne ; Université de Liège - ULiège > Département de pharmacie > Chimie toxicologique
Pinto, Emmanuel ; Centre Hospitalier Universitaire de Liège - CHU > Psychiatrie et psychologie médicale
Ansseau, Marc ; Université de Liège - ULiège > Département des sciences cliniques > Psychiatrie et psychologie médicale
Plomteux, Guy ; Université de Liège - ULiège > Services généraux (Faculté de médecine) > Relations académiques et scientifiques (Médecine)
Language :
English
Title :
Relationship between Clinical Effects, Serum Drug Concentration, and Concurrent Drug Interactions in Depressed Patients Treated with Citalopram, Fluoxetine, Clomipramine, Paroxetine or Venlafaxine
Alternative titles :
[fr] Relation entre les effets cliniques et la concentration plasmatique pour plusieurs antidépresseurs
Publication date :
August 2000
Journal title :
Human Psychopharmacology
ISSN :
0885-6222
eISSN :
1099-1077
Publisher :
John Wiley & Sons, Hoboken, United States - New Jersey
Ananth J. (1988) Treatment-resistant depression. Psychother Psychosom 67:61-70.
Baumann P. (1990) Apports et limites des dosages plasmatiques d'antidepresseurs. Neuro Psychiatrie 5:155-164.
Beasley C.M., Bosomworth J.C., Wernicke J.F. (1990) Fluoxetine: Relationships among dose, response adverse events, and plasma concentration in the treatment of depression. Psychopharmacol Bull 26:18-24.
Benkert O., Szegedi A., Wetzel H. (1996) Minimum effective dose for antidepressants - An obligatory requirement for antidepressant drug evaluation. Int Clin Psychopharmacol 11:177-185.
Charlier C., Ansseau M., Pinto E., Andrien F., Plomteux G. (1999) Le controle therapeutique des medicaments antidepresseurs. Ann Biol Clin 57:463-468.
De Oliveira I.R., Do Prado-Lima P.A.S., Samuel-Lajeunesse B. (1989) Monitoring of tricyclic antidepressant plasma levels and clinical response: A review of literature. Part I. Psychiatry Psychobiol 4:43-60.
Demyttenaere K. (1997) Compliance during treatment with antidepressants. J Affect Disord 43:27-39.
Flanagan R.J. (1998) Guidelines for the interpretation of analytical toxicology results and unit of measurement conversion factors. Ann Clin Biochem 35:261-267.
Goodnick P.J. (1994) Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 27:307-330.
Kelly M.W., Perry P.J., Sheldon G.H., Garvey M.J. (1989) Fluoxetine and norfluoxetine concentrations and anti-depressant response. Ther Drug Monit 11:165-170.
Meyer U.A., Amrein R., Balant L.P., Bertilsson L., Eichelbaum M., Guentert T.W., Henauer S., Jackson P., Laux G., Mikkelsen H., Peck C., Pollock B.G., Priest R., Sjoqvist F., Delini-Slula A. (1996) Antidepressants and drug metabolizing enzymes - Expert group report. Acta Psychiatr Scand 93:71-79.
Montgomery S.A., Asberg M. (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:328-389.
Montgomery S.A., Kasper S. (1998) Side effects, dropouts from treatment and cost consequences. Int Clin Psychopharmacol 13(2):1-5.
Owen J.R., Nemeroff C.B. (1998) New antidepressants and the cytochrome P450 system: Focus on venlafaxine, nefazodone and mirtazapine. Depress Anxiety 751:24-32.
Shasha M., Lyons J.S., O'Mahoney M.T., Rosenberg A., Miller S.I., Howard K.I. (1997) Serotonin reuptake inhibitors and the adequacy of antidepressant treatment. Int J Psychiatr Med 27:83-92.
Thase M.E., Rush A.J. (1997) When at first you don't succeed: Sequential strategies for antidepressant non-responders. J Clin Psychiatry 58(13):23-29.
Uges D.R.A. (1996) Therapeutic and toxic drug concentrations. TIAFT Bull 26:34.
